MetLife Investment Management LLC Has $136,000 Stake in Sana Biotechnology, Inc. $SANA

MetLife Investment Management LLC boosted its holdings in Sana Biotechnology, Inc. (NASDAQ:SANA) by 192.4% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 80,866 shares of the company’s stock after purchasing an additional 53,208 shares during the quarter. MetLife Investment Management LLC’s holdings in Sana Biotechnology were worth $136,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Tower Research Capital LLC TRC raised its stake in Sana Biotechnology by 229.9% in the 4th quarter. Tower Research Capital LLC TRC now owns 15,136 shares of the company’s stock worth $25,000 after purchasing an additional 10,548 shares in the last quarter. Pallas Capital Advisors LLC acquired a new stake in Sana Biotechnology in the 1st quarter worth about $29,000. Ameriprise Financial Inc. acquired a new stake in Sana Biotechnology in the 4th quarter worth about $29,000. BNP Paribas Financial Markets acquired a new stake in Sana Biotechnology in the 4th quarter worth about $34,000. Finally, Focus Partners Wealth acquired a new stake in Sana Biotechnology in the 4th quarter worth about $35,000. Institutional investors and hedge funds own 88.23% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on SANA. JMP Securities restated a “market outperform” rating and issued a $5.00 target price on shares of Sana Biotechnology in a research report on Tuesday, June 24th. Morgan Stanley began coverage on shares of Sana Biotechnology in a research report on Thursday, July 3rd. They set an “overweight” rating and a $12.00 price objective for the company. Six research analysts have rated the stock with a Buy rating, According to data from MarketBeat, Sana Biotechnology has an average rating of “Buy” and a consensus target price of $8.00.

Sana Biotechnology Stock Up 0.7%

SANA opened at $3.02 on Wednesday. The stock has a market cap of $718.19 million, a PE ratio of -2.85 and a beta of 1.88. The company has a fifty day moving average of $3.72 and a 200-day moving average of $2.70. Sana Biotechnology, Inc. has a twelve month low of $1.26 and a twelve month high of $7.30.

Sana Biotechnology (NASDAQ:SANA) last issued its earnings results on Monday, August 11th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.04. Sell-side analysts anticipate that Sana Biotechnology, Inc. will post -1.16 EPS for the current fiscal year.

Sana Biotechnology Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.